Imperial College London


Faculty of MedicineDepartment of Infectious Disease

Professor of Practice



+44 (0)20 3315 5098j.gilmour




J.2.3 Immunology DepartmentChelsea and Westminster HospitalChelsea and Westminster Campus





Jill Gilmour is the Executive Director for Human Immunology at the International AIDS Vaccine Initiative (IAVI) and Principal Investigator of the IAVI Human Immunology Laboratory (HIL) at Imperial College London.  With more than 20 years of experience in HIV research and development, focusing on the African epidemic, she is responsible for IAVI’s Clinical Laboratory Program and staff internationally, overseeing research strategy, immune monitoring, data, quality, and scientific and laboratory capacity building to support HIV vaccine trials and epidemiology studies.  Dr Gilmour is also the founding member and Director of the HIL, leading a team of 40.  Dr Gilmour engages with a broad spectrum of International Donors, participates in many international steering and working groups, and is the PI/co-investigator on a number of grants and awards to support assay validation, reference testing and training for global consortia and vaccine initiatives, including PATH-MVI, WHO-Ebola, Wellcome Trust UK-HIV Vaccine Consortia, CAVD-VIMC and the European HIV Vaccine Alliance and the European AIDS Vaccine Initiative, two consortia of the European Union’s Horizon 2020 health program.

Dr Gilmour has overseen IAVI’s laboratory capacity-building program from site selection through the full accreditation of 12 laboratories across Africa and India, and has developed and co-lead multi-center immunology and epidemiology studies in East and Southern Africa.  She is a founder and IAVI Scientific Director for the VISTA Initiative (Vaccine Immunology Science and Technology for Africa), developing strategic partnerships to encourage collaboration, technology transfer and training opportunities with partners in Europe, the United States, Africa and India.

Prior to joining IAVI in 2001, Dr Gilmour’s research focused on the host immune system in HIV transmission notably in the African epidemic.  She held a post-doctoral fellowship of the UK MRC AIDS directed program and was a Lecturer at Imperial College London, and worked with MRC/UVRI Uganda Research Unit on AIDS to develop its cellular immunology laboratory, mentoring Ph.D. students and technical staff based in the United Kingdom and Uganda.  She has co-authored more than 100 peer-reviewed scientific publications and holds a Hon Readership in Vaccine Immunology at Imperial College London.  Dr Gilmour obtained her Honors Degree and Ph.D. from the University of Edinburgh.  



Price MA, Kilembe W, Ruzagira E, et al., 2020, Cohort profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery., Int J Epidemiol

Macharia GN, Yue L, Staller E, et al., 2020, Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4(+)T cell decline and increased immune activation during acute infection, Plos Pathogens, Vol:16, ISSN:1553-7366, Pages:1-22

El-Badry E, Macharia G, Claiborne D, et al., 2020, Better Viral Control despite Higher CD4(+) T Cell Activation during Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol, Journal of Virology, Vol:94, ISSN:0022-538X

Kasprowicz VO, Chopera D, Waddilove KD, et al., 2020, African-led health research and capacity building- is it working?, Bmc Public Health, Vol:20

Brooks K, Jones BR, Dilernia DA, et al., 2020, HIV-1 variants are archived throughout infection and persist in the reservoir, Plos Pathogens, Vol:16, ISSN:1553-7366

More Publications